Target Patient Population: Patients with Active Lupus Nephritis Class III-IV, +/- V
Study Overview:
Part 1: To determine whether Iptacopan (study drug) in combination with SoC is safe and effective in patients with Class III or IV active lupus nephritis with or without co-existing class V features, assessed as achieving complete renal response (CRR) based on UPCR.
Part 2: To evaluate a lower dose of Iptacopan (study drug) with SoC as an alternative to corticosteroids
Study Timeline: Anticipated patient participation is 12 Months, 14 visits to the clinic
Number of Patients Currently Active in the Trial: 0